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The Golden Helix Pharmacogenomics Days are international scientific meetings aiming to educate healthcare
professionals and biomedical scientists about pharmacogenomics and personalized medicine. In this meeting report,
we provide an overview of the scientific lectures and the topics discussed during the 6th Golden Helix
Pharmacogenomics Day that was held in Belgrade, Serbia last June 5, 2012. The scientific program included lectures
by the local and international speakers from Europe and the United States.
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Pharmacogenomics is referred to as the study of varia-
tions in DNA sequence and gene expression as related
to drug efficacy and toxicity. It is a base for the imple-
mentation of personalized medicine, a young but rapidly
advancing field of health care. The goal of personalized
medicine is to identify genomic and clinical information
in order to predict individual risk of developing disease,
the course of disease and response to treatment of a
person.
The Golden Helix Pharmacogenomics Days are inter-
national educational scientific meetings that are orga-
nized by the Golden Helix Institute of Biomedical
Research [1,2] jointly with the local academic institutions
in major cities with large academic hospitals. The aim of
these meetings is to provide timely updates on the field
of pharmacogenomics and personalized medicine to the
local biomedical scientists, healthcare providers and bio-
medical students in order to educate and inform them
on the application of pharmacogenomics in modern
medical practice and to bring together faculty members
from universities and research institutes from the local
scientific arena working in the field of pharmacogenom-
ics in order to initiate collaborative projects in this field* Correspondence: branka.petrucev@gmail.com
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medium, provided the original work is properto the benefit of the society. Previous Golden Helix
Pharmacogenomics Days have been organized in Athens
(Greece: May 7, 2009), Thessaloniki (Greece: April 15,
2010) and Alexandroupolis (Greece: April 8, 2011),
Cagliari (Italy: October 8, 2011) and Msida (Malta:
December 3, 2011) [3].
The 6th Golden Helix Pharmacogenomics Day was
organized in Belgrade, Serbia by the Golden Helix
Institute of Biomedical Research, the Institute of Molec-
ular Genetics and Genetic Engineering, University of
Belgrade, and the National Association for Enhancement
and Development of Regenerative Medicine, Belgrade,
Republic of Serbia, endorsed by the Pharmacogenomics
for Every Nation Initiative (PGENI) and Ministry of
Education and Science, Republic of Serbia, and supported
by the Complete Genomics, Cryo-Save, Imel Group and
Illumina.
The meeting was attended by over 180 registered parti-
cipants. In this meeting report, we provide an overview
of the scientific lectures and present the highlights of this
meeting.The 6th Golden Helix Pharmacogenomics Day
The most powerful tools of disease research and trans-
lational medicine are the next-generation sequencing
methods. As a result of their development, we also entered
into the golden age of pharmacogenomics. Dr Radoje
Drmanac (chief scientific officer, Complete Genomics,
Mountain View, CA, USA) delivered the keynote lecturess article distributed under the terms of the Creative Commons Attribution
by/2.0), which permits unrestricted use, distribution, and reproduction in any
ly cited.
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hybridization, which led to the industrialization of whole
genome sequencing. Drmanac first got the idea how to
revolutionize sequencing method while he was working
at the Genetic Engineering Center in Belgrade (now
Institute of Molecular Genetics and Genetic Engineering,
University of Belgrade). While Complete Genomics cur-
rently has the capacity to sequence 1000 genomes per
month, their next big goal is to sequence 100 times more
genomes during the same time and with an improved
quality, and most importantly, lower costs [4,5]. The
whole genome sequencing (WGS) is the ultimate genetic
test which is taken only once and used throughout life-
time. It has a diagnostic and predictive values and it will
become essential in disease prevention and personalized
treatment leading to a longer healthy life [6].
Snezana Pajovic (University of Nis, Faculty of Medi-
cine, Serbia) addressed the importance of pharmacoge-
nomic polymorphisms from the medical point of view.
Modern medicine recognizes inter-individual differences
in the capability of persons to metabolize a given drug.
Contrary to transient adverse drug effects, e.g. caused by
allergies, if a person has a genetic disability to metabolize
a drug, it will be persistent through lifetime. Pajovic
stressed the importance of performing pharmacogenomic
tests for the benefit of the patient and as a paradigm of
personalized medicine. Furthermore, physicians could
easily make a drug choice which is especially important
when a life-long therapy is needed. At the end, she
pointed out that the pharmacogenomic testing should be
used to reduce the overall healthcare costs.
Sonja Pavlovic (University of Belgrade, Institute of
Molecular Genetics and Genetic Engineering, Serbia)
pointed out that the physicians growingly recognize the
need to perform genetic tests in order to optimize the
treatment dose. Giving the state of the art of pharmaco-
genomic testing, Pavlovic highlighted that there is an
immense number of candidates for pharmacogenomic
testing [7] and that professionals could be confused what
genetic variations should be taken into account. There-
fore, Pavlovic identified obligatory and recommended
pharmacogenomic markers (approved by FDA, EMA,
and PMDA) [8,9]. The most relevant pharmacogenomic
tests are routinely performed in Serbian accredited la-
boratories. Unfortunately, the main obstacle of broader
use of these tests is that patients have to pay the testing
themselves. At the end, Pavlovic reviewed the state of
pharmacogenomics in Serbia saying that there is a solid
biomedical and molecular-genetic research base that has
already been followed by clinical studies and has been
implemented in the clinical practice. This progress is
mainly accomplished through research projects funded
by Ministry of Education and Science of Republic of
Serbia, which also endorsed this event.Vita Dolzan (University of Ljubljana, Faculty of
Medicine, Institute of Biochemistry, Slovenia) and Sabina
Semiz (University of Sarajevo, Faculty of Pharmacy,
Bosnia and Herzegovina) gave valuable insights into
the pharmacogenomics in Slovenia and Bosnia and
Herzegovina. They presented centers that perform phar-
macogenomic tests and have infrastructure for pharma-
cogenomic research in these countries. Dolzan also
presented recently organized interdisciplinary doctoral
program in biomedicine as a base for education of future
pharmacogenomic experts in Slovenia. Both Dolzan and
Semiz are participating, on behalf of their countries, in
the PGENI that is coordinated in Europe by the Golden
Helix Institute of Biomedical Research [10,11].
George P Patrinos (University of Patras, Patras,
Greece) outlined the steps that can be taken by countries
with good health system infrastructure, but there are
insufficient resources for individual patient genotyping in
routine practice to improve patient treatment and reduce
healthcare cost. Patrinos underlined that Serbia is one of
the 18 European countries that are currently participat-
ing in the PGENI, which also endorsed this event [10].
On this occasion, Patrinos revealed preliminary data of
pharmacogenomic analysis of 50 Serbian healthy volun-
teers which will be used in the future to modulate phar-
macogenomic practice in Serbia. These results pointed
out to some very interesting differences between com-
mon pharmacogenomic marker allele frequencies in the
Caucasians and Serbian population, further supporting
the importance of PGENI to rationalize drug use in
developing countries [11].
Florian Graedler (Illumina, Munich, Germany) gave an
overview of the next generation sequencing and array
technologies and their applications in pharmacogenom-
ics. Serbian experience of pharmacogenetics in clinical
practice was presented by Lidija Krivokapic-Dokmanovic
(University of Belgrade, University Children’s Hospital,
Serbia). A thiopurine drug 6-mercaptopurine is used in
maintenance phase of the standard therapy in childhood
ALL. In the retrospective and prospective study of
thiopurine toxicity in Serbian childhood ALL patients,
Dokmanovic explained how the modified therapeutic
protocol for treatment of the ALL children was intro-
duced at the University Children’s Hospital in Serbia
[12]. In the prospective study, a dose of thiopurine drugs
was modified according to the patient’s TPMT genotype.
These patients, even heterozygous TPMT carriers, had
no hematological complications, no febrile neutropenias,
and no therapy interruptions [13]. This novel modifica-
tion of standard therapeutic protocol has significantly
improved childhood ALL treatment in Serbia.
Staying focused on the same drug, Branka Zukic
(University of Belgrade, Institute of Molecular Genetics
and Genetic Engineering, Serbia) gave an overview of the
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marker, the variable number of tandem repeats (VNTR
alleles), in the promoter region of the TPMT gene. The
distribution and frequency of VNTR alleles and VNTR
genotype of Serbian population were presented. The
transcriptional potential of each VNTR allele detected
was determined in functional CAT assays [14]. Also, the
hypothesis for the role of VNTR region in regulation of
TPMT gene transcription was presented. Zukic further
discussed the latest experiments on thiopurine influence
on VNTR region. Decrease of TPMT gene promoter ac-
tivity under the influence of thiopurine drugs was VNTR
architecture-dependent [15]. Furthermore, five VNTR
alleles are pointed out that display extreme susceptibility
for thiopurine therapy. She concluded that preliminary
results of the clinical studies confirmed that VNTR geno-
type could be a novel pharmacogenetic marker which
can be truly used for personalizing thiopurine therapy.
Next, Maja Stojiljkovic (University of Belgrade, Insti-
tute of Molecular Genetics and Genetic Engineering,
Serbia) pointed out that the most frequent variant of uri-
dine diphosphate glucoronosyltransferase 1A1 (UGT1A1)
gene, (TA)7TAA, represents one of the clinically most
relevant pharmacogenomic markers. Moreover, this vari-
ant is equally important as a diagnostic marker for
patients with Gilbert’s syndrome. At this symposium,
Stojiljkovic presented the first data about variants in the
UGT1A1 gene found in Serbian Gilbert’s syndrome
patients and healthy volunteers. Not only that patients
with Gilbert’s syndrome were genotyped so that their
hyperbilirubinemia is not confused with more severe
hepatic lesions, but also the data deduced from healthy
volunteers proved that (TA)7TAA pharmacogenomic
marker is very important in Serbian population. Stojiljkovic
also underlined the third but not least application of the
UGT1A1 genetic test on (TA)7TAA. She reminded that
this test should be used in clinical trials with investiga-
tional drugs to differentiate between persons not know-
ing to have Gilbert’s syndrome and those in whom
hyperbilirubinemia is caused by liver toxicity of a tested
drug.
Thromboembolism is a significant cause of morbidity
and mortality in adults, and giving that its treatment
relies on anticoagulants, adverse effect of the treatment
itself could be severe and even lethal. Ljiljana Rakicevic
(University of Belgrade, Institute of Molecular Genetics
and Genetic Engineering, Serbia) focused her lecture on
fine optimization of the drug dose based on pharmacoge-
nomic tests. Giving that anticoagulant drugs have narrow
therapeutic range, she highlighted that besides informa-
tion about genomic variants, attention must be paid to a
drug’s interaction with other drugs and the existence
of other health conditions and diseases. Rakicevic pre-
sented Serbian experience with significant markers forthromboembolism prevention and treatment [16]. These
pharmacogenomic markers are one of the many exam-
ples of significant inter-ethnical differences that provide
important point of view for implementation of pharma-
cogenetic testing in different populations.
An added value of this symposium was its interdiscipli-
narity. Side by side with biomedical experts, Hajrija
Mujovic (Institute of Social Sciences, Serbia) shared her
view on the legal issues of pharmacogenomic testing in
Serbia. She defined that the increasing development of
biomedicine led to formation of a new legal discipline
called medical rights. Mujovic pointed out that principal
legal issues of the medical rights are based on social justi-
fication and responsibility, health improvement, equality
in treatment, non-discrimination, freedom of choice,
respect of individual dignity and integrity, personal
security and respect of privacy. She added that informed
consent is always a prerequisite for genetic testing and
that a person should understand what for their sample is
going to be used. Furthermore, one must not feel obli-
gated to perform any genetic test because of the fear that
otherwise he/she would not be treated properly. Mujovic
concluded the talk with a reminder that research practice
in general, and thus pharmacogenomic testing as well,
should be conducted with respect to the Universal
Declaration on Bioethics and Human Rights and Inter-
national Declaration on Human Genetic Data, both
issued by UNESCO [17,18].
The 6th Golden Helix Pharmacogenomics Day in
Belgrade provided information on research and applica-
tion of pharmacogenomics in Serbia and neighboring
countries. The most recent data on common clinically
applicable pharmacogenomic markers were presented.
Also, the importance of WGS was emphasized. WGS is
of particular value when it comes to rare pharmacoge-
nomic variants, those that, due to their low frequency,
are not screened with usual pharmacogenomic tests, and
therefore, cause severe adverse drug effect.
Conclusions
As with the previous meetings of this international series,
the 6th Golden Helix Pharmacogenomics Day high-
lighted various areas of interest in pharmacogenomics,
where many internationally renowned scientists gave
excellent overviews of the existing applications and
demonstrated the way and the rapid pace that the field is
moving. The Golden Helix Institute of Biomedical
Research aims to establish the Golden Helix Pharmaco-
genomics Days as one of the main educational and out-
reach activities for PGENI [10,11] in European countries,
such that healthcare professionals and biomedical scien-
tists are aware of the benefits of this promising new dis-
cipline so that the adoption of pharmacogenomics in the
mainstream clinical practice is expedited, particularly in
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cogenomic applications will significantly benefit the gen-
eral public in these countries. The final message to take
home is that education of general public and profes-
sionals on the pharmacogenomics is essential for the suc-
cess of personalized medicine.
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